CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.16B, above the global median of $1.15B
- FinancialsAltman Z-Score 9.96: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.16BUSDvs all stocks (USD)
Revenue (TTM)
86.93MUSDvs all stocks (USD)
Profit Margin
-1.70%Beta
0.8610xvs all stocks
52-Week Change
193.89%vs all stocks
Market Capitalization
1.16BUSDvs all stocks (USD)
Enterprise Value
1.17BUSDvs all stocks (USD)
Forward P/E
22.51xPrice to Sales (TTM)
13.33xPrice to Book (MRQ)
37.82xEnterprise to Revenue
13.47xEnterprise to EBITDA
105.62xGross Margin
60.72%Profit Margin
-1.70%Operating Margin
11.39%Return on Assets (TTM)
4.76%Return on Equity (TTM)
-5.36%Revenue (TTM)
86.93MUSDvs all stocks (USD)
Revenue per Share (TTM)
3.22USDUpdated Jul 18, 2026Quarterly Revenue Growth
40.40%Gross Profit (TTM)
51.92MUSDvs all stocks (USD)
EBITDA (TTM)
3.20MUSDvs all stocks (USD)
Net Income (TTM)
-1.48MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
40.41%Operating Cash Flow (TTM)
15.84MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
2.44MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
79.95MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
37.21MUSDFY2025 · Dec 31, 2025Gross Profit
42.74MUSDFY2025 · Dec 31, 2025Operating Income
-844.00KUSDvs all stocks (USD)
Pre-tax Income
-4.56MUSDFY2025 · Dec 31, 2025Income Tax Expense
43.00KUSDFY2025 · Dec 31, 2025Net Income
-4.60MUSDFY2025 · Dec 31, 2025EBIT
-844.00KUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
3.20MUSDFY2025 · Dec 31, 2025Research & Development
7.76MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
35.82MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-4.60MUSDFY2025 · Dec 31, 2025Operating Cash Flow
8.44MUSDFY2025 · Dec 31, 2025Free Cash Flow
8.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
25.94MUSDFY2025 · Dec 31, 2025Income Tax Paid
118.00KUSDFY2025 · Dec 31, 2025Interest Paid
3.33MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-4.60MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
4.04MUSDFY2025 · Dec 31, 2025Stock-based Compensation
5.51MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.83MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-6.40MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.81MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.76MUSDFY2025 · Dec 31, 2025Capital Expenditures
-333.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-333.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
27.36MSharesUpdated Jul 18, 2026Float Shares
21.02MSharesUpdated Jul 18, 2026Shares Short
1.45MSharesUpdated Jul 18, 2026Short Ratio
3.48daysvs all stocks
Short % of Shares Outstanding
7.44%vs all stocks
% Held by Insiders
5.32%vs all stocks
% Held by Institutions
66.08%vs all stocks
Total Cash (MRQ)
19.66MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7180USDUpdated Jul 18, 2026Total Debt (MRQ)
31.26MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.02xCurrent Ratio (MRQ)
1.21xBook Value per Share (MRQ)
1.12USDUpdated Jul 18, 2026Total Assets
92.11MUSDvs all stocks (USD)
Total Current Assets
60.58MUSDFY2025 · Dec 31, 2025Total Liabilities
65.96MUSDFY2025 · Dec 31, 2025Total Non-current Assets
31.53MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
27.47MUSDFY2025 · Dec 31, 2025Total Current Liabilities
38.49MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
25.94MUSDFY2025 · Dec 31, 2025Accounts Receivable
11.76MUSDFY2025 · Dec 31, 2025Inventory
15.42MUSDFY2025 · Dec 31, 2025Accounts Payable
10.98MUSDFY2025 · Dec 31, 2025Short-term Debt
8.79MUSDFY2025 · Dec 31, 2025Long-term Debt
22.23MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
5.24MUSDFY2025 · Dec 31, 2025Common Stock (Book)
27.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-112.49MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
26.15MUSDvs all stocks (USD)
52-Week Low
13.78USDUpdated Jul 18, 202652-Week High
42.65USDUpdated Jul 18, 202652-Week Change
193.89%vs all stocks
Beta
0.8610xvs all stocks
50-Day MA
33.16USDUpdated Jul 18, 2026200-Day MA
22.43USDUpdated Jul 18, 2026Avg 10-Day Volume
483.12KSharesUpdated Jul 18, 2026Avg 30-Day Volume
447.19KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.0600USDUpdated Jul 18, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Cash Flow, Profit, and Revenue All Growing
Free cash flow and gross profit have both grown over four years, with revenue up in each of the last three.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.61Profit Margin: -0.02
Financial Health
Altman Z-Score 9.96: safe zoneNotable
Altman Z-Score: 9.96
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.16B, above the global median of $1.15BNotable
Market cap (USD): 1,159,244,590Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BioGaia AB
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shantou Institute of Ultrasonic Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sanofi Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Northeast Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
MeiraGTx Holdings plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guilin Sanjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Glass House Brands Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Avanos Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Collegium Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule